.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
US Department of Justice
UBS
QuintilesIMS
McKesson
Chubb
Dow
Merck
Baxter
US Army

Generated: July 24, 2017

DrugPatentWatch Database Preview

Amprenavir - Generic Drug Details

« Back to Dashboard

What are the generic sources for amprenavir and what is the scope of amprenavir freedom to operate?

Amprenavir
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amprenavir has fifty patent family members in forty countries.

There are five drug master file entries for amprenavir.

Summary for Generic Name: amprenavir

Tradenames:1
Patents:2
Applicants:1
NDAs:2
Drug Master File Entries: see list5
Bulk Api Vendors: see list52
Clinical Trials: see list63
Patent Applications: see list8,640
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:amprenavir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-001Apr 15, 1999DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039-001Apr 15, 1999DISCNYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-002Apr 15, 1999DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: amprenavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-002Apr 15, 1999► Subscribe► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-001Apr 15, 1999► Subscribe► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-001Apr 15, 1999► Subscribe► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039-001Apr 15, 1999► Subscribe► Subscribe
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-002Apr 15, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: amprenavir

Country Document Number Estimated Expiration
Colombia4790151► Subscribe
Slovakia126998► Subscribe
Argentina006345► Subscribe
Austria230602► Subscribe
Estonia04093► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AMPRENAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C0015France► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIQUE; REG. NO/DATE: EU/1/07/282/001-002 20040712
C/GB01/009United Kingdom► SubscribePRODUCT NAME: AMPRENAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: CH 5507201 19990512; CH 5507202 & 5507301 19990512; UK EU/1/00/148/001 20001020; UK EU/1/00/148/002 20001020; UK EU/1/001/148/003 20001020; UK EU/1/00/148/004 20001020
2001Austria► SubscribePRODUCT NAME: AMPRENAVIR, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/00/148/001 - EU/1/00/148/004 20001020; FIRST REGISTRATION: LI 55072 01, 55072 02 UND 55073 01 19990512
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Express Scripts
Chinese Patent Office
Fuji
Chubb
US Department of Justice
Covington
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot